Trichuris suis ova therapy for allergic rhinitis: A randomized, double-blind, placebo- controlled clinical trial Peter Bager, PhD, John Arnved, MD, Steen Rønborg, PhD, Jan Wohlfahrt, PhD, Lars K. Poulsen, PhD, Tine Westergaard, PhD, Henning Willads Petersen, PharmD, Bjarne Kristensen, MSc, Stig Thamsborg, PhD, Allan Roepstorff, PhD, Christian Kapel, PhD, Mads Melbye, DMSc Journal of Allergy and Clinical Immunology Volume 125, Issue 1, Pages 123-130.e3 (January 2010) DOI: 10.1016/j.jaci.2009.08.006 Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig 1 CONSORT study flow diagram (A) and treatment compliance∗ (B) for 100 subjects with grass pollen–induced allergic rhinitis in a clinical trial of TSO, Denmark, 2008. Journal of Allergy and Clinical Immunology 2010 125, 123-130.e3DOI: (10.1016/j.jaci.2009.08.006) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig 2 Percentage of subjects who reported treatment-emergent diarrhea by number of days enrolled in a randomized clinical trial of TSO, Denmark, 2008. Tx, Treatment no. x. Journal of Allergy and Clinical Immunology 2010 125, 123-130.e3DOI: (10.1016/j.jaci.2009.08.006) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig 3 Eosinophil counts and T suis–specific antibody titers measured at 3 sampling visits in 96 adults with grass pollen–induced allergic rhinitis in a randomized clinical trial of TSO (red line) and placebo (blue line), Denmark, 2008. Journal of Allergy and Clinical Immunology 2010 125, 123-130.e3DOI: (10.1016/j.jaci.2009.08.006) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions